Pluri Net Income From Continuing Ops Over Time
| PLUR Stock | USD 3.56 0.01 0.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pluri Performance and Pluri Correlation. Can Biotechnology industry sustain growth momentum? Does Pluri have expansion opportunities? Factors like these will boost the valuation of Pluri. Anticipated expansion of Pluri directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Pluri demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (3.56) | Revenue Per Share | Quarterly Revenue Growth 3.146 | Return On Assets | Return On Equity |
Pluri Inc's market price often diverges from its book value, the accounting figure shown on Pluri's balance sheet. Smart investors calculate Pluri's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Pluri's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pluri's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pluri should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pluri's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Pluri Inc and related stocks such as AN2 Therapeutics, Q32 Bio, and NextCure Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTX | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (21.5 M) | (41 M) | (59.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| QTTB | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (37.6 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (36.6 M) | (69.4 M) | (74.7 M) | (65.6 M) | (55.7 M) | (50.1 M) | (52.6 M) |
| IBIO | (6.2 M) | (6.2 M) | (6.2 M) | (3.7 M) | (6.6 M) | (10.7 M) | (16.1 M) | (16.1 M) | (17.6 M) | (16.4 M) | (23.2 M) | (50.3 M) | (29.3 M) | (15.4 M) | (18.4 M) | (16.5 M) | (17.4 M) |
| BOLD | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (45.9 M) | (49.4 M) | (65.4 M) | (58.8 M) | (61.8 M) |
| PSTV | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (3.3 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (14.9 M) | (15.7 M) |
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (31.1 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| INTS | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| SABS | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | 20.1 M | (17.1 M) | (18.7 M) | (27.2 M) | (34.1 M) | (30.7 M) | (29.2 M) |
| JSPR | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (36.8 M) | (51.2 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
Pluri Inc and related stocks such as AN2 Therapeutics, Q32 Bio, and NextCure Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Pluri Inc | PLUR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | MATAM Advanced Technology |
| Exchange | NASDAQ Exchange |
USD 3.56
Additional Tools for Pluri Stock Analysis
When running Pluri's price analysis, check to measure Pluri's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluri is operating at the current time. Most of Pluri's value examination focuses on studying past and present price action to predict the probability of Pluri's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluri's price. Additionally, you may evaluate how the addition of Pluri to your portfolios can decrease your overall portfolio volatility.